



Powered by the Sharekhan 3R Research Philosophy

3R MATRIX

	+	=	-
Right Sector (RS)	✓	■	■
Right Quality (RQ)	✓	■	■
Right Valuation (RV)	✓	■	■

+ Positive = Neutral - Negative

What has changed in 3R MATRIX

	Old		New
RS	■	↔	■
RQ	■	↔	■
RV	■	↔	■

ESG Disclosure Score **NEW**

ESG RISK RATING	18.07			
Updated Jun 08, 2023				
Low Risk				
NEGL	LOW	MED	HIGH	SEVERE
0-10	10-20	20-30	30-40	40+

Source: Morningstar


Company details

Market cap:	Rs. 25,722 cr
52-week high/low:	Rs. 427 / 174
NSE volume: (No of shares)	25.3 lakh
BSE code:	500877
NSE code:	APOLLOTYRE
Free float: (No of shares)	39.8 cr

Shareholding (%)

Promoters	37.3
FII	22.4
DII	17.8
Others	22.5

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	4.1	27.8	25.5	129.6
Relative to Sensex	2.3	19.3	23.6	107.6

Sharekhan Research, Bloomberg

Apollo Tyres Ltd

Diligent steer for profitability

Automobiles	Sharekhan code: APOLLOTYRE		
Reco/View: Buy	↔	CMP: Rs. 405	Price Target: Rs. 472 ↑
↑ Upgrade	↔ Maintain	↓ Downgrade	

Summary

- Given the firm's dominating position in the domestic TBR market, the fact that Vision 2026 is on track, the emphasis on premiumisation, and the preference for profitability over simple volume growth, we retain our Buy recommendation on the stock with a revised PT of Rs. 472.
- ATL is on track to achieve its target for FY2026 as EBITDA margin in FY2023 stands at 13.5% against its target for FY2026 at over 15%.
- Management is looking for volume-based single-digit growth in the Indian business and flat growth in the European business in FY2024.
- The stock trades at a P/E multiple of 14.2x and EV/EBITDA multiple of 7.0x its FY2025 estimates.

We have visited ATL's AP plant (Andhra Pradesh) and interacted with the management. AP plant has been its modern plant with a high level of automation and digitised infrastructure. Further, ATL is on track to achieve its targets for 2026, as it has already achieved 13.5% EBITDA margin and revenue of USD3.1 billion in FY2023 against its target of EBITDA margin at >15% and revenue of USD5 bn by 2026. ATL assumes for a mid to high single-digit growth in the Indian business and is looking for flat growth in the European business in FY2024, while it would continue to focus on profitability via premiumisation, digitization, and raw-material (RM) cost tail wind. Capacity utilisation in India and Europe stands at ~76% and ~80%, respectively, and management is focussing more on capacity utilisation in the next two years than lining up huge capex. The company may require expanding its capacity in the PCR segment from FY2026; however, management has not budgeted it yet. We remain optimistic about the company's growth prospects and expect it to benefit from its strategy of deleveraging its balance sheet, improving operating leverage, and focusing on firm capital allocation and cash management going forward. We continue to maintain our Buy rating on the stock with a revised price target (PT) of Rs. 472.

- Modernise plant and high level of automation:** ATL's plant in AP, which came in 2020, is spread over 257 acres and has the capacity of 15,000 passenger car tyres (PCR) per day and 3,000 truck bus radial tyres (TBR) per day. The facility is fully airconditioned and has a high level of automation and digitisation. The plant has adequate space available to expand further in future. The company assumes that the brownfield expansion in future at its AP plant would be cost-effective due to optimum utilization of common equipment and infra set-up. The AP plant follows a centre spine concept by setting up a common mould shop, utility areas, and test centres between PCR and TBR lines, which help it in reducing material handling cost, reduction in production lead time, and lowers energy consumption. Increased level of automation helped it in reducing employee cost and offering high-quality products. Similarly, implementation of industry 4.0 practises helps it in developing better operation practices. Management continues to focus on profitable growth and is strategically concentrating on capacity debottlenecking in the near term in place of setting up a large green field project at least for the next two years.
- Looking for volume-led growth in the Indian business:** Management is continuously looking for profitable volume growth in the domestic business. Hence, it is focussing more on the benefits of its brand equity than merely expanding low-margin volumes in the OEM category. In a spree to retain higher margins, management is ready to give up certain OEM deals if it is coming out without any desired level of margins. Management foresees green shoots in the MHCV replacement segment, while PCR replacement demand is still weak. Management claims for a 21% market share in the PCR segment and close to 29-30% market share in the MHCV segment. ATL is looking for mid to high single-digit growth in the Indian business, led by volume recovery and better product mix as prices are not expected to increase significantly from here. Further, steady RM cost trend and focus on premiumisation would continue to support profitability levels.
- Expects flat growth in the European business:** Economic headwinds and geopolitical worries are still causing problems in European markets. ATL continues to gain market share in European markets, backed by its focus on quality and brand equity. Although volume growth is facing headwinds, management is focussing on improvement in product mix for better profitability. Considering the macro trends, management has guided for flat growth in the European business in FY2024. The company is targeting to outperform the industry's growth on account of focus on premiumisation in its product mix. It is assumed that destocking in European markets is gradually easing out.

Our Call

Valuation – Maintain Buy rating with a revised PT of Rs. 472: We observed that ATL has been actively focussing on the implementation of industry 4.0 practices and efficient manufacturing processes at its plant for an optimum utilisation of resources. The higher level of automation is helping in containing employee costs in limits and keeping the quality of the products under check. Further, ATL is emphasising more on playing its brand equity in the replacement market in place of remaining a piggyback on OEMs, as it is ready to give up certain OEM businesses if it would not justify the desired EBITDA margin. Further, the company has been on track in achieving its targets for FY2026, as its EBITDA margin has already improved by 120 bps y-o-y to 13.5% in FY2023 and it has been targeting for >15% kind of EBITDA margin in 2026. While ATL has been continuously focussing on premium products and improvement in the product mix, the soft RM cost trend along with its own cost-control initiatives are likely to support it in sustaining high EBITDA margin. Given the firm's dominating position in the domestic TBR market, the fact that Vision 2026 is on track, the emphasis on premiumisation, and the preference for profitability over simple volume growth, we retain our Buy recommendation on the stock with a revised PT of Rs. 472.

Key Risks

ATL derives about ~30% of its revenue from its European operations, which exposes it to currency risks. Any adverse movement in the INR-Euro pair would affect its financial performance.

Valuation (Consolidated)

Particulars	FY21	FY22	FY23P	FY24E	FY25E
Revenues	17,397	20,948	24,568	27,537	29,684
Growth (%)	6.6	20.4	17.3	12.1	7.8
EBIDTA	2,797	2,574	3,314	3,970	4,427
OPM (%)	16.1	12.3	13.5	14.4	14.9
Adjusted PAT	958	644	1,082	1,503	1,817
% YoY growth	101.1	-32.7	67.9	39.0	20.9
Adjusted EPS (Rs)	15.1	10.1	17.0	23.7	28.6
P/E (x)	26.9	39.9	23.8	17.1	14.2
P/B (x)	2.2	2.2	2.0	1.8	1.6
EV/EBITDA (x)	11.3	12.2	9.3	7.8	7.0
RoE (%)	8.4	5.5	8.4	10.6	11.4
RoCE (%)	6.6	5.1	7.6	9.1	9.8

Source: Company; Sharekhan estimates

Vision 2026: On track

- ◆ ATL has reiterated its goal to achieve revenue of USD5bn with 15% plus EBITDA margin, 12-15% EBITDA margin and net debt/EBITDA below 2x by 2026.
- ◆ ATL has already achieved revenue of USD3 bn, EBITDA margin of 13.5%, ROCE of 10.1%, and net debt/EBITDA of 1.4x.
- ◆ ATL has outperformed the domestic tyre industry in the last three years, as its standalone business recorded a 18% revenue CAGR compared to 16% CAGR of the Indian tyre industry over FY2020-FY2023.
- ◆ The continued focus on profitability and asset-light business model have resulted in sharp improvement in ROCE and FCF generation, as it generated FCF of Rs. 636.9 crore in FY2023 (vs. negative FCF of Rs. 771.0 crore in FY2020) and recorded ROCE of 10.1% (vs 4.9% in FY2020).
- ◆ In line with its vision plan, the company has been continuously focussing on implementing industry 4.0 practices in its plant and is looking for high level of digitisation in its operations. With its focus on digitisation, the company has been increasing its expenditure on new advanced technologies. In FY2023, the expenditure on advanced technologies stood at 32% of its IT spends compared to 8% in FY2020.
- ◆ The company aims to be carbon neutral by 2050.
- ◆ The near-term focus will be on increasing business through product differentiation, enhancing penetration in new markets (both domestic and exports), brand building, R&D investments, and ramping up capacity.

Indian business: Looking for mid to high single-digit growth in FY2024

- ◆ In the Indian market, OEM demand has been steady, while the replacement market has been improving.
- ◆ Replacement demand in the MHCV segment is better than that of the PCR segment.
- ◆ The company is observing green shoots in the MHCV replacement market; however, the PCR segment is yet to recover in the replacement market.
- ◆ The company is looking for a mid to high single-digit growth in the Indian business in FY2024, backed by volume growth as there is little room for price hikes due to competition and supportive RM cost trend.
- ◆ In the replacement market, it claims for a 21% market share in the PCR segment and 28-29% market share in the MHCV segment.
- ◆ The demand for large-size tyres has been rising as people switch from driving cars to driving SUVs. As a result, it is anticipated that the PCR segment's profitability trend would also improve.
- ◆ ATL continues to focus on increasing digitization, improving product quality, and premiumising products and profitability.

Focus on profitability

- ◆ RM cost trend is expected to be steady in the medium term.
- ◆ Given the macro headwinds, export growth from India is expected to remain moderate in FY2024.
- ◆ With steady RM cost, pricing discipline in the industry is expected to remain in the medium term in the tyre industry.
- ◆ ATL is focusing more on profitability than plan vanilla volume growth, as it is ready to give up certain OEM deals if it would not justify its desired profitability.

European market: Flat growth in FY2024

- ◆ European business has registered a 10% revenue CAGR over FY2020 to FY2023 and has witnessed a sharp improvement in its operating performance.

- ◆ In FY2023, the European business reported revenue of Euro688 mn (vs. Euro 523 mn in FY2020) and EBITDA of Euro109 mn (vs. loss of Euro 9mn in FY20)
- ◆ The company is looking for flat growth in the European business in FY2024 due to macro challenges.
- ◆ However, it continues to aim for a better product mix and, hence, for improved profitability in the European business.
- ◆ ATL's product mix continues to be strong as the UHP/ UUHP segment constituted 43% of the PCLT in FY2023 compared to 32% in FY2020.
- ◆ The company has been gaining market share in UUHP tyres and agri tyre segment in the European market.

Capex: Maintained capex guidance at Rs. 1,100 crore for FY2024

- ◆ Gradually, capex intensity has been moderating as the company has been focussing more on capacity utilisation, strong balance sheet, and high levels of profitability. The company has incurred a cumulative capex of Rs. 2,576.8 crore in the last two years compared to cumulative capex of Rs. 6,319.5 crore over FY2019-FY2021.
- ◆ The company has adequate capacity to drive its growth in FY2024 and FY2025 and has maintained its capex guidance for FY2024.
- ◆ The company is not planning a significantly high capex for the near term and is aiming to follow the capex-light model for the next two years.
- ◆ It maintained capex guidance of Rs. 1,100 crore for FY2024, which would largely be related to maintenance and de-bottlenecking and not growth capex.
- ◆ Out of the total capex of Rs. 1,100 crore, ATL has earmarked Rs. 680 crore for its Indian business and the rest is for the European business.
- ◆ In the medium term, the company plans to cater to Indian markets through its Indian plants, European markets through Indian and Hungarian plants, and U.S. market through Indian as well as European plants.
- ◆ While management has indicated that it would have adequate capacity for FY2024-FY2025, it indicates that the future capex would be need based. Management has indicated that AP plant has adequate room to expand as its lay out would help in saving costs due to better utilisation of common equipment and infrastructure.
- ◆ Management assumes with an outflow of Rs. 1,500 crore to Rs. 2,000 crore, it can set up a capacity for 8,000 tyres per day in India and the same capacity can be set up in Europe with an investment of Euro 200 mn. However, it has not fixed up a new capacity build-up plan yet.

Consolidated revenue mix in FY2023


- ◆ Geography-wise revenue mix: APMEA: ~67%, Europe: ~29%, Others: ~4%
- ◆ Channel-wise revenue mix: OEM: ~23%, Replacement: ~77%
- ◆ Segment-wise revenue mix: Truck and Bus: ~43%, passenger vehicles: ~37%, Farm: ~10%, light truck: ~6%, others: ~5%

Capacity utilisation

- ◆ India: ~76%
- ◆ Europe: ~ 82%


Financials in charts

Revenue : Geographical Mix (%)




Source: Company, Sharekhan Research

Revenue and Growth Trends




Source: Company, Sharekhan Research

EBITDA and OPM Trends




Source: Company, Sharekhan Research

PAT and PAT Margin Trends




Source: Company, Sharekhan Research

ROE Trend (%)



Source: Company, Sharekhan Research

ROCE Trend (%)



Source: Company, Sharekhan Research

Outlook and Valuation

■ Sector Outlook – Strong recovery eyed

We expect the domestic tyre industry to benefit from recovery in automobile sales in rural and semi-urban markets, driven by pent-up demand, preference for personal mobility, and faster-than-expected recovery in infrastructure, mining, and other economic activities. The tyre industry is well positioned to gain momentum in future, backed by higher OEM offtake. The ripple effect of OEM demand is likely to result in steady growth for replacement demand. Further, sharp correction in RM basket augurs well for the surge in profitability.


■ Company Outlook – Convincing strategy to achieve a profitable growth model

Management has laid down its long-term targets to achieve revenue of US\$5 billion by FY2026, an EBITDA margin profile to reach at least 15%, ROCE of 12-15%, and net debt to EBITDA of less than 2x. Replacement volumes are expected to recover with a recovery in macro-economic activities. The overseas business is expected to do well because of a richer product mix and gradual capacity additions.

■ Valuation – Maintain Buy rating with revised PT of Rs.472

We observed that ATL has been actively focussing on the implementation of industry 4.0 practices and efficient manufacturing processes at its plant for an optimum utilisation of resources. The higher level of automation is helping in containing employee costs in limits and keeping the quality of the products under check. Further, ATL is emphasising more on playing its brand equity in the replacement market in place of remaining a piggyback on OEMs, as it is ready to give up certain OEM businesses if it would not justify the desired EBITDA margin. Further, the company has been on track in achieving its targets for FY2026, as its EBITDA margin has already improved by 120 bps y-o-y to 13.5% in FY2023 and it has been targeting for >15% kind of EBITDA margin in 2026. While ATL has been continuously focussing on premium products and improvement in the product mix, the soft RM cost trend along with its own cost-control initiatives is likely to support it in sustaining high EBITDA margin. Given the firm's dominating position in the domestic TBR market, the fact that Vision 2026 is on track, the emphasis on premiumisation, and the preference for profitability over simple volume growth, we retain our Buy recommendation on the stock with a revised PT of Rs. 472.

One-year forward P/E (x) band



Source: Sharekhan Research

Peer Comparison

Particulars	CMP	P/E (x)			EV/EBITDA (x)			RoCE (%)		
	Rs/Share	FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E
Apollo Tyres	405	23.8	17.1	14.2	9.3	7.8	7.0	7.6	9.1	9.8
Balkrishna Industries	2,391	40.4	30.6	25.9	27.6	19.4	16.3	10.3	13.0	13.8

Source: Company, Sharekhan estimates

About company

ATL is the second largest tyre manufacturer in India. The company is a diversified player present in India as well as Europe. APMEA business contributes about 67% to its revenue, while European business contributes about 29%. With its recent entry into the two-wheeler space, ATL has become a full-fledged tyre player present across automotive categories viz. passenger vehicles, commercial vehicles, and two-wheelers. The OEM segment contributes about 23% to its revenue, while the replacement segment accounts for the balance 77%.

Investment theme

ATL is one of the leading tyre companies in India, with a leadership position in the largest truck and bus tyre segment. The company is also one of India's leading players in the passenger vehicle segment. Over the past few years, ATL has been increasing its presence globally and acquired businesses in Europe, which has opened new markets for the company and strengthened its R&D capabilities globally. ATL is expected to gain market share in other segments and in multiple geographies (e.g. Vredestein in passenger vehicles and Apollo in truck and bus segments), driven by a strong brand, R&D, technology, and distribution network. In addition, the company will operationally improve its margin, aided by specialisation of Dutch plant (through a significant uptick in cost competitiveness, given ramping up production in Hungary); cost reductions through the digitalisation of its businesses; and improvement in passenger vehicle mix.

Key Risks

ATL derives about 30% of its revenue from European operations, which exposes it to currency risks. Any adverse movement in the INR-Euro pair would impact its financial performance.

Additional Data

Key management personnel

Onkar Singh Kanwar	Chairman and Managing Director
Neeraj Kanwar	Vice Chairman and Managing Director
Gaurav Kumar	Chief Financial Officer

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Sunrays Properties & Investments Co. Pvt. Ltd.	19.78
2	Apollo Finance Group Ltd.	12.06
3	Emerald Sage Investment Ltd.	9.93
4	HDFC Asset Management Co. Ltd.	8.63
5	White Iris Investment Ltd.	8.04
6	Classic Industries & Exports Ltd.	2.94
7	Kotak Mahindra Asset Management Co. Ltd./India	2.68
8	Norges Bank	2.33
9	The Vanguard Group Inc.	2.22
10	Mehta Ashwin Shantilal	2.13

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/ reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. (CIN): - U99999MH1995PLC087498. Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-6115000.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669.

Compliance Officer: Ms. Binkle Oza; Tel: 022-61169602; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022- 41523200/022- 33054600